Business
CooperCompanies Appoints Paul Keel to its Board of Directors
SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board. “We are delighted to welcome Paul to our Board as a new Director,” said Colleen Jay, Chair of the Board of CooperCompanies. “His experience as a CEO in the medical de
About this update from Smiths Group Plc
[{"type":"image","alt":"CooperCompanies","displaySize":"","headline":null,"caption":"CooperCompanies","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/fdd02d6c67a52c74a2d266382db6a571"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fCwRAH.smUtA8qp7RZb65w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg0/https://media.zenfs.com/en/globenewswire.com/fdd02d6c67a52c74a2d266382db6a571","width":300,"height":60}},"lazy":false},{"type":"text","content":"SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board.","length":333,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Paul to our Board as a new Director,” said Colleen Jay, Chair of the Board of CooperCompanies. “His experience as a CEO in the medical device sector, along with a successful track record of leading complex global operations, will be a significant asset as Cooper continues to execute its strategy and create long-term value for patients, customers, and shareholders.”","length":396,"tagName":"p"},{"type":"text","content":"Mr. Keel has served as President and Chief Executive Officer of Envista Holdings Corporation (NYSE: NVST), a global specialty medical technology company, since 2024. Prior to joining Envista, Mr. Keel served as CEO of Smiths Group plc (LON: SMIN), a diversified global industrial technology company and FTSE constituent, from 2021 to 2024. Earlier, he spent 16 years at 3M, serving in various leadership roles, including Group President of 3M Consumer Business, President of 3M Medical, President of 3M Unitek, SVP of Manufacturing & Supply Chain, and SVP of Marketing, Sales & Business Development. Mr. Keel’s career also includes roles at General Mills, General Electric, Norwest Equity Partners, and McKinsey & Company. He holds an MBA from Harvard Business School and a BA in Economics from Carleton College.","length":824,"tagName":"p"},{"type":"text","content":"About CooperCompanies","length":21,"tagName":"p"},{"type":"text","content":"CooperCompanies (Nasdaq: COO) is a leading global medical device ...